Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab + regorafenib for third-line MSS colorectal liver metastasis
ChiCTR2400085593Phase 2Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Jun 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab and regorafenib in colorectal adenocarcinoma and colorectal cancer liver metastasis (CRLM), sponsored by Huashan Hospital. Primary endpoints: Disease control rate, Duration of response and 1 more. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
cadonilimabregorafenib
03
Conditions
colorectal adenocarcinomacolorectal cancer liver metastasis (CRLM)
Beyond the preview
Go deeper on ChiCTR2400085593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085593.